|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM301338280 |
| 003 |
DE-627 |
| 005 |
20231225104422.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.108260
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1004.xml
|
| 035 |
|
|
|a (DE-627)NLM301338280
|
| 035 |
|
|
|a (NLM)31525445
|
| 035 |
|
|
|a (PII)S1521-6616(19)30323-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Oikawa, Yoichi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Significance of peripheral mononuclear cells producing interferon-γ in response to insulin B:9-23-related peptides in subtypes of type 1 diabetes
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.05.2020
|
| 500 |
|
|
|a Date Revised 19.05.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Type 1 diabetes is largely caused by β-cell destruction through anti-islet autoimmunity. Reportedly, interferon (IFN)-γ-secreting peripheral blood mononuclear cells (PBMCs) specific to four insulin B-chain amino acid 9-23-related peptides (B:9-23rPep) were increased in type 1 diabetes participants. This study aimed to investigate the PBMC frequencies in subtypes of type 1 diabetes using enzyme-linked immunospot assay. In this cross-sectional study, peripheral blood samples were obtained from 148 participants including 72 with acute-onset type 1 diabetes (AT1D), 51 with slowly progressive insulin-dependent diabetes mellitus (SPIDDM), and 25 with type 2 diabetes. The frequency of B:9-23rPep-specific IFN-γ-producing PBMCs was significantly higher in AT1D participants than in SPIDDM and type 2 diabetes participants. Meanwhile, a significant inverse correlation was observed between the PMBC frequencies and insulin secretion capacity in SPIDDM participants. These findings suggest that the increased peripheral B:9-23rPep-specific IFN-γ immunoreactivity reflects decreased functional β-cell mass and greater disease activity of type 1 diabetes
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Autoimmune
|
| 650 |
|
4 |
|a Enzyme-linked immunospot assay
|
| 650 |
|
4 |
|a Insulin
|
| 650 |
|
4 |
|a Interferon-γ
|
| 650 |
|
4 |
|a Type 1 diabetes
|
| 650 |
|
7 |
|a Autoantigens
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a insulin B (9-23)
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Sakamoto, Kumiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Satomura, Atsushi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Haisa, Akifumi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Katsuki, Takeshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hattori, Yutaka
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Inoue, Ikuo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Noda, Mitsuhiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shimada, Akira
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 208(2019) vom: 25. Nov., Seite 108260
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:208
|g year:2019
|g day:25
|g month:11
|g pages:108260
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.108260
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 208
|j 2019
|b 25
|c 11
|h 108260
|